Skip to Content
Merck

O9512

Sigma-Aldrich

Oxaliplatin

Apoptosis inducer, powder

Synonym(s):

[SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-N,N′)[ethanedioata(2--)-O,O’]platinum

Sign Into View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C8H14N2O4Pt
CAS Number:
61825-94-3
Molecular Weight:
397.29
MDL number:
MFCD00866327
UNSPSC Code:
12352200
PubChem Substance ID:
329818942
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Oxaliplatin, powder

form

powder

Quality Level

100

originator

Sanofi Aventis

storage temp.

2-8°C

SMILES string

O=C1O[Pt]OC1=O.N[C@@H]2CCCC[C@H]2N

InChI

1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1

InChI key

ZROHGHOFXNOHSO-BNTLRKBRSA-L

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Oxaliplatin has been used:
  • as a chemotherapeutic agent in colon rectal adenocarcinoma SW480 cells by cell viability assay
  • for monitoring cell survival in hepatocellular carcinoma HepG2 and HepG2/R cells by MTT assay
  • to determine the growth inhibitory effect on human breast adenocarcinoma MDA-MB-231 cells

Biochem/physiol Actions

Oxaliplatin a platinum analogue, causes DNA damage and cell death by binding to DNA and forming inter and intrastrand crosslinks preventing replication and transcription. Oxaliplatin is an anti-tumor agent with activity against colorectal cancer; cytotoxicity follows the formation of adducts with DNA. Oxaliplatin is an approved drug for treating colorectal cancer. It is an active ingredient in FOLFOX (Folinic acid:5-FU:oxaliplatin in the ratio 1:10:1 of micromolar concentrations respectively). Oxaliplatin causes both acute and chronic neurotoxicity in patients in a dose dependent manner and is reversible either by reducing or stopping the drug.

Features and Benefits

This compound is a featured product for ADME Tox and Apoptosis research. Discover more featured ADME Tox and Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Health hazardCorrosion
GHS08,GHS05

Signal Word

Danger

Hazard Classifications

Carc. 2 - Eye Dam. 1 - Lact. - Muta. 2 - Repr. 1B - Resp. Sens. 1B - Skin Sens. 1 - STOT RE 1

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCP7198
MKCM9763
MKCL6788
MKCH9259
MKCG3721

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

SUMOylation alterations are associated with multidrug resistance in hepatocellular carcinoma
Qin Y, et al.
Molecular Medicine Reports, 9(3), 877-881 (2014)
Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study
Votanopoulos KI, et al.
Annals of Surgical Oncology, 1-9 (2018)
Expression of an oncogenic BARD1 splice variant impairs homologous recombination and predicts response to PARP-1 inhibitor therapy in colon cancer
Ozden O, et al.
Scientific Reports, 6, 26273-26273 (2016)
Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue
Jamieson SMF, et al.
Molecular Pain, 5(1), 66-66 (2009)
Bernard Nordlinger et al.
The Lancet. Oncology, 14(12), 1208-1215 (2013-10-15)
Previous results of the EORTC intergroup trial 40983 showed that perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) increases progression-free survival (PFS) compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer. Here we present
View All Related Papers

Articles

세포 주기 연구를 위한 생체 활성 저분자

증식하는 세포에서 세포 주기는 4단계로 구성됩니다. Gap 1(G1)은 유사분열과 세포 성장을 특징으로 하는 DNA 복제 사이의 기간입니다. DNA 복제는 합성(S)기에 일어나며, 세포 분열을 위한 성장 및 준비를 하는 Gap 2(G2)가 뒤따릅니다. 이 세 단계는 함께 세포주기의 간기 단계를 구성합니다. 간기 이후에 분열(M)기가 뒤따릅니다.

DNA Damage and Repair

DNA damage and repair mechanism is vital for maintaining DNA integrity. Damage to cellular DNA is involved in mutagenesis, the development of cancer among others.

Discover Bioactive Small Molecules for Cell Cycle

Cell cycle phases (G1, S, G2, M) regulate cell growth, DNA replication, and division in proliferating cells.

Bioactive Molecules for Apoptosis

Apoptosis regulation involves multiple pathways and molecules for cellular homeostasis.

See All

Related Content

세포사멸 연구를 위한 생체 활성 저분자

세포사멸, 즉 세포예정사(PCD)는 여러 생물학적 시스템에서 불필요하고 감염되거나 변형된 세포를 제거하기 위한 선택적인 과정입니다. 이 과정은 다세포 기관의 항상성에서 역할을 수행하고 있기 때문에, 세포자멸사는 많은 조절 및 효과인자 분자에 의해 두 가지 주요 경로를 통해서 철저하게 조절됩니다.

ADME/Tox를 위한 생체 활성 저분자

ADME/Tox를 위한 생체 활성 저분자

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service